JW Pharmaceutical acquires license of ‘emicizumab,’ innovative hemophilia A treatment

Published: 2017-05-15 14:02:10

Updated: 2017-05-15 14:02:10

JW Pharmaceutical acquired a license of a hemophilia A treatment improved in administration convenience in Korea.

JW Pharmaceutical(CEO Sung-Kwon Han, Young-Seop Shin) announced on the 11^th that it signed an exclusive license agreement of ‘emicizumab(development code: ACE910)’ in Korea with Chugai Pharmaceutical(President Tatsuro Kosaka), a subsidiary of Roche Group.

‘Emicizumab,’ a genetical...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.